Estudo de coorte retrospectiva | Uso de nirmatrelvir e desfechos de Covid-19 grave durante o aumento da variante Ômicron.
29 Ago, 2022 | 17:16h
Comentário no Twitter
During the clinical rollout of nirmatrelvir in Israel in early 2022, most patients (78%) had previous SARS-CoV-2 immunity. Benefit was seen among patients at highest risk for Covid-19 progression, such as those 65+. https://t.co/O6CxzDdIfH pic.twitter.com/ccCaCCh15i
— NEJM (@NEJM) August 24, 2022